Medicine Matters oncology

Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.

A retrospective analysis has found a significantly higher incidence of hyperglycemia among breast cancer patients treated with alpelisib in standard care than on clinical trials.

Findings from the TARGET-TP trial support a risk-directed approach to thromboprophylaxis in ambulatory patients with gastrointestinal or lung cancer receiving systemic anticancer treatment.

The novel KRAS inhibitor divarasib has shown promise in previously treated patients with advanced solid tumors harboring a KRAS G12C mutation.

A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.

Supplementing standard systemic therapy with tumor treating fields prolongs the overall survival of previously treated patients with metastatic NSCLC.

An analysis of the CCC19 registry has demonstrated a significant link between receipt of anticancer therapies within 3 months of a COVID-19 diagnosis and an elevated risk for venous thromboembolism

Patients with treatment-naïve, early-stage or isolated parenchymal recurrent NSCLC benefit from the addition of immunotherapy to stereotactic ablative radiotherapy, indicate phase 2 results.

Preliminary MASAI trial results indicate that AI-supported mammography has a similar rate of breast cancer detection to standard double reading while reducing the screen-reading workload.

The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

First-line treatment with atezolizumab significantly improves the overall survival of platinum-ineligible patients with locally advanced or metastatic non-small-cell lung cancer relative to chemotherapy.

An analysis of the KRYSTAL-1 study indicates that adagrasib has intracranial activity in people with KRAS G12C-mutated non-small-cell lung cancer and untreated CNS metastases.

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

The KEYNOTE-671 trial points to a significant improvement in event-free survival for patients with early-stage, non-small-cell lung cancer with use of pembrolizumab before and after surgery.

Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR-mutated, early-stage non-small-cell lung cancer, show trial results.

Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

The use of immune checkpoint inhibitors is not associated with excess toxicity in people living with HIV and a concomitant diagnosis of cancer, indicate real-world results.

A chart review of the Veterans Affairs health system indicates that there are around 14 cases of prostate cancer per year among transgender women.